Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus later in patients who have acute ischemic stroke caused by atrial fibrillation and who develop bleeding complications after emergency endovascular treatment. This multicenter, prospective, open-label, randomized controlled trial aims to determine the best timing to initiate DOAC therapy to balance stroke recurrence and bleeding risks. Participants are assigned to one of two groups one begins any DOAC within 4 weeks after stroke onset early initiation, and the other starts DOACs between 4 and 8 weeks after stroke onset delayed initiation. The trial compares these two timing strategies following emergency endovascular therapy to see which approach is safer and more effective. During the study, participants will be monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Additional assessments include quality of life, functional recovery, vascular events, and bleeding complications up to one year. Researchers will track hospital stay length and use clinical scales such as the modified Rankin Scale and EQ-5D-5L questionnaire to evaluate recovery and health status. The total study duration spans the treatment and follow-up periods up to one year.